The treatment of aHUS involves:
aHUS, complement, thrombotic microangiopathy, eculizumab, factor H, membrane cofactor protein, ravulizumab. atypical hemolytic syndrome
Long-term safety of C5 inhibition is unclear. Limited data suggest some patients (especially those with MCP mutations or anti-FH antibodies that remit) may discontinue after sustained remission >12-24 months. However, 20-30% relapse upon discontinuation, sometimes with irreversible renal loss. Decision requires shared decision-making and close monitoring. The treatment of aHUS involves: aHUS, complement, thrombotic
[Generated for Academic Use] Date: April 13, 2026 Dosed every 8 weeks after loading
Modified eculizumab with increased neonatal Fc receptor (FcRn) binding → half-life ~50 days vs 11 days for eculizumab. Dosed every 8 weeks after loading. Non-inferior efficacy with reduced infusion burden.
Diagnosing aHUS is often difficult because it mimics other conditions, such as Thrombotic Thrombocytopenic Purpura (TTP) or Shiga toxin-producing E. coli HUS (STEC-HUS). Doctors typically reach an aHUS diagnosis by "exclusion," ruling out other causes of TMA through blood tests and genetic screening. Treatment Evolution: From Plasma to Biologics